YAbS







Abagovomab Terminated Vaccine, Anti-idiotype antibody

Antibody Information

Entry ID 2606
INN Abagovomab
Status Terminated
Drug code(s) None
Brand name None
mAb sequence source mAb murine
General Molecular Category Vaccine, Anti-idiotype antibody
Format, general category Full length Ab
Format details None
Isotype (Fc) IgG1
Light chain isotype kappa
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) MUC16 idiotype
Indications of clinical studies Ovarian cancer
Primary therapeutic area Cancer

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Terminated at Phase 2/3
Status Inactive
Start of clinical phase (IND filing or first Phase 1) December 15, 2002
Start of Phase 2
Start of Phase 3 December 15, 2006
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Menarini Group
Licensee/Partner Memorial Sloan Kettering Cancer Center
Comments about company or candidate Menarini terminates the phase III MIMOSA trial in Ovarian cancer in USA and European Union (NCT00418574, started in Dec 2006). NCT00058435 Phase 1 started in Dec 2002; non-commercial sponsor.
Full address of company Florence, Italy
Europe
Italy
https://www.menarini.com/en-us/about-us

Description/comment

Abagovomab is an anti-idiotypic monoclonal antibody that mimics a specific epitope on the tumour-associated antigen, CA125. Cancer vaccine mechanism of action

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None